Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway

QIANQIAN TANG1,2, YUNFEI WANG1, LANJING MA3, MEILING DING3, TINGYU LI3, YONGZAN NIE3 and ZHENGYI GU1

1Key Laboratory of Xinjiang Uighur Medicine, Xinjiang Institute of Materia Medica, Urumqi 830004; 2College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830011; 3State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710032, P.R. China

Received June 12, 2017; Accepted December 1, 2017

DOI: 10.3892/or.2018.6184

Abstract. Gastric cancer (GC) is one of the most common malignancies of the digestive tract. Adriamycin (ADR) has been widely utilized in various chemotherapy regimens for treating GC, yet its long-term application may increase drug resistance resulting in treatment failure. Increasing evidence shows that bioactive natural products can be used as chemotherapeutic sensitizers that can significantly improve chemotherapy sensitivity. Peiminine (PMI) is a biologically active component extracted from Fritillaria walujewii Regel. Thus, in the present study, we aimed to investigate whether peiminine (PMI) alters the chemosensitivity of GC to adriamycin (ADR). GC cells were treated with ADR with or without PMI. MTT assay, flow cytometry and a nude mouse tumor xenograft model of SGC7901 cells were used to evaluate the chemosensitization activity of PMI combined with ADR. Western blotting was used to examine the expression of cyclin D1 and cleaved PARP. The RayBio® Human RTK phosphorylation antibody array kit was used to test the differential protein expression. Compared with the ADR group, PMI combined with ADR significantly suppressed cell proliferation and induced cell apoptosis in vitro. The growth curve and tumor weight of the tumor xenografts were significantly decreased in mice treated with the combination of PMI and ADR. However, the organs showed no obvious abnormality after treatment with PMI plus ADR. The expression of cyclin D1 was decreased and the level of cleaved PARP was increased after treatment with PMI and ADR. The expression of p-EGFR and p-FAK was downregulated in cells treated with PMI and ADR, and the validation of p-EGFR and p-FAK was in accordance with the result of the phosphorylation antibody array kit. PMI may serve as a new chemosensitizer by inhibiting the proliferation and inducing the apoptosis to enhance the chemotherapeutic drug sensitivity of ADR in GC.

Introduction

Gastric cancer (GC), one of the most common malignancies, is the third leading cause of cancer-related death worldwide (1,2). To date, chemotherapeutic agents have been considered as a treatment option for various types of tumors. However, their clinical efficiency is hampered by cytotoxicity and chemotherapy resistance (3,4). Adriamycin (ADR), a cell cycle non-specific drug, shows a variety of therapeutic effects on tumors as it inhibits DNA and RNA synthesis. ADR and its derivatives have been widely utilized in various chemotherapy regimens for treating GC (5). Despite its obvious antitumor effects, it is reported to show marked toxicity. However, the toxicity is usually inconspicuous and before diagnosis of the adverse effects, the treatment may negatively affect various organs such as the brain, heart and kidneys (6). Moreover, its long-term application may increase drug resistance and result in treatment failure (7). Therefore, it is urgent to identify novel drugs with which to enhance the drug sensitivity of ADR and reduce its toxicity in clinical practice.

Increasing evidence shows that bioactive natural products can be used as chemotherapeutic sensitizers that can significantly improve chemotherapy sensitivity (8). In China, traditional Chinese medicine (TCM) has been used as a new origin for anticancer drugs for use as novel adjuvant chemotherapy treatments (NACTs) to improve the effectiveness of chemotherapy and to reduce side-effects and resistance of cancer chemotherapies (9). For example, gambogenic acid has been reported to increase the chemosensitivity of breast cancer cells to ADR via suppressing the PTEN/PI3K/AKT pathway (10). Meanwhile, Choi et al revealed that decursin found in Angelica gigas Nakai (AGN) could inhibit the proliferation of ADR-resistant ovarian
cancer cells and induce apoptosis in the presence of ADR via blocking P-glycoprotein expression (11).

Peiminine (PMI) (Fig. 1A), is a biologically active component extracted from *Fritillaria walujewii* Regel of the *Liliaceae* family known as Xinjiang-Bei-Mu. Along with other alkaloids extracted from *Fritillaria*, PMI was reported to show biological effects as an antitussive and a relaxant of bronchial smooth muscle (12,13). In addition, PMI was found to suppress colorectal cancer cell growth and cell proliferation by inducing autophagic cell death (14). In the present study, we focused on the sensitization effects of PMI on chemotherapy using ADR in the treatment of GC. Our data showed that PMI enhanced the chemotherapy sensitivity of GC to ADR, which suggested that the combination of PMI and ADR may be useful for treating human GC.

**Materials and methods**

**Drugs.** PMI (MW, 429.64 g/mol) with a purity of >98% was obtained from the Xinjiang Institute of Materia Medica (Urumqi, China). It was solubilized in dimethyl sulfoxide (DMSO) before usage. ADR was purchased from Sigma-Aldrich (St. Louis, MO, USA).

**Cell culture.** Human GC cell lines SGC7901 (Academy of Military Medical Science, Beijing, China), SGC7901/ADR (human ADR-resistant cells) and SGC7901/VCR (human vincristine-resistant cells) (both from State Key Laboratory of Cancer Biology, Xi’an, China), and BGC823 (Academy of Military Medical Science) were maintained in our laboratory previously described (16). The organs were assessed using H&E staining. Immunohistochemistry was performed for Ki67, as photographed and then fixed with 10% formaldehyde for H&E staining. Immunohistochemistry was performed for Ki67, as previously described (16). The organs were assessed using H&E staining.

**Human RTK phosphorylation antibody array.** The RayBio® Human RTK phosphorylation antibody array kit (RayBiotech Inc., Norcross, GA, USA) was used for the Human RTK phosphorylation antibody array. Proteins were extracted from SGC7901 cells treated with ADR (1.0 µM) and ADR (1.0 µM) + PMI (50.0 µM), respectively. Seventy-one proteins were tested according to the manufacturer's instructions. The images were scanned by ImageQuant LAS 4000 (GE Healthcare Corp., Piscataway, NJ, USA) with high resolution. The data were extracted and analyzed by the instrument analysis software.

**In vitro drug sensitivity assay.** Female BALB/c nude mice obtained from the Experimental Animal Center of the Fourth Military Medical University were used for the drug sensitivity assay. For the tumor challenge, SGC7901 cells (2.0x10⁶) were subcutaneously injected into the left side of nude mice. Two weeks later, the animals were divided into the following groups: control (n=5), received intraperitoneal (i.p.) injections of saline; ADR group (n=5), receiving i.p. injections of ADR (2.0 mg/kg); PMI group (n=5), receiving i.p. injections of PMI (2.5 mg/kg); and ADR and PMI group, receiving a combination of ADR (2.0 mg/kg) and PMI (2.5 mg/kg). All groups were injected every two days during the treatment course. Tumor volume (V) was measured using a digital caliper every two days after chemotherapy according to the formula: V = LW²/2 (L, tumor length, W, tumor width).

**Hematoxylin and eosin (H&E) staining and immunohistochemistry.** After the sacrifice of the animals subjected to tumor challenge and treatment, the tumors were weighed, photographed and then fixed with 10% formaldehyde for H&E staining. Immunohistochemistry was performed for Ki67, as previously described (16). The organs were assessed using H&E staining.

**In vitro apoptosis assay.** Cell apoptosis in the four groups (e.g. DMSO, ADR, PMI and PMI + ADR group) was detected using Dead Cell Apoptosis Kit with Annexin V APC and SYTOX® Green (Invitrogen-Molecular Probes, Eugene, OR, USA) for flow cytometry as previously described (15). All the tests were performed at least in triplicate.

**In vivo drug sensitivity assay.** Female BALB/c nude mice obtained from the Experimental Animal Center of the Fourth Military Medical University were used for the drug sensitivity assay. For the tumor challenge, SGC7901 cells (2.0x10⁶) were subcutaneously injected into the left side of nude mice. Two weeks later, the animals were divided into the following groups: control (n=5), received intraperitoneal (i.p.) injections of saline; ADR group (n=5), receiving i.p. injections of ADR (2.0 mg/kg); PMI group (n=5), receiving i.p. injections of PMI (2.5 mg/kg); and ADR and PMI group, receiving a combination of ADR (2.0 mg/kg) and PMI (2.5 mg/kg). All groups were injected every two days during the treatment course. Tumor volume (V) was measured using a digital caliper every two days after chemotherapy according to the formula: V = LW²/2 (L, tumor length, W, tumor width).

**Western blotting.** SGC7901 cells treated with DMSO, ADR (1.0 µM), PMI (50.0 µM) and ADR (1.0 µM) + PMI (50.0 µM), respectively, were homogenized in RIPA buffer (Beyotime, Jiangsu, China) containing protease inhibitors and phosphatase inhibitors (Roche, Basel, Switzerland). Total cell lysates were electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred onto NC membranes (Sigma-Aldrich). The membranes were blocked in 5% non-fat milk and incubated with primary antibody including rabbit anti-human cyclin D1 (#2922), cl-PARP (#5625), EGRF (#4405), FAK (#3285), p-FAK (Tyr397; #3283), p-FAK (Tyr576; #3281) (all from
Cell Signaling Technology, Inc, Beverly, MA, USA), p-EGFR (Tyr1068; #ab32430; Abcam, Cambridge, MA, USA) (dilution ratio, 1:1,000; animal origins, rabbit anti-human), overnight at 4°C, and then incubated with the peroxidase-conjugated goat anti-rabbit secondary antibody (1:1,000; Abcam) for 1 h at room temperature. The same membrane was probed for β-actin for loading control. Blots were scanned by Molecular Imager ChemiDoc XRS + Imaging System with Quantity one software (Bio-Rad).

Statistical analysis. All data are expressed as mean ± standard error of mean. Two-tailed Student's t-test or an one-way ANOVA test was used to analyze the intergroup comparisons. Statistical tests were performed using SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.

Results

Effects of PMI on the cell viability of the GC cell lines. To determine the cell cytotoxicity of PMI, we determined the cell viability using MTT assay, in which GC cell lines were treated with PMI at concentrations of 12.5, 25, 50, 100, 200 and 400 µM, respectively. Compared to the vehicle (DMSO), a high dose of PMI partly inhibited cell growth (Fig. 1B). A concentration of 50.0 µM of PMI was used as the optimal concentration based on viability results for a non-toxic dose. GC, gastric cancer; PMI, peiminine.

PMI enhances the chemotherapeutic drug sensitivity in GC cell lines. To investigate the chemotherapeutic drug sensitivity of PMI, we compared the efficiency of ADR combined with PMI and ADR alone in SGC7901, BGC823, SGC7901/ADR and SGC/7901/VCR cells, respectively. The combination of
ADR and PMI conferred a significant toxic effect on these cells compared with those treated only using ADR (Fig. 2A-D), featured by significant inhibition rates (P<0.05) and a decrease in IC₅₀ (P<0.05; Fig. 2E).

**PMI combined with ADR induces the apoptosis of GC cells.** Flow cytometry was carried out to analyze the apoptosis in SGC7901 and SGC7901/ADR cells after treatment with PMI, ADR or the combination of PMI and ADR. The results showed that the combination of PMI and ADR induced significant cell apoptosis compared with treatment with ADR alone (P<0.05; Fig. 3). Thus, PMI enhanced the chemotherapy sensitivity of ADR via induction of apoptosis in the GC cells.

**Chemosensitive effects of PMI in vivo.** To investigate whether PMI enhances the ADR chemotherapeutic sensitivity of GC cells in vivo, we transplanted SGC7901 cells into nude mice. The tumor volume was significantly decreased in the PMI combined with ADR group compared with the control, PMI and ADR groups, respectively (Fig. 4A and B). This indicated that PMI enhanced the chemotherapeutic sensitivity of ADR. After sacrifice of the animals, the tumors were isolated, weighed and photographed (Fig. 4C). The combination of ADR and PMI induced significant inhibition activity of tumor volume compared with that of the control group and ADR group (P<0.01). Whereas, PMI induced no tumor inhibition activity compared to the control group (Fig. 4D).

Regarding the side-effects of the drug combination, no significant difference was noted in the body weight in the PMI group compared to the control group. However, a significant decrease was noted in the body weight in the ADR and ADR combined with PMI group compared to the control group (Fig. 4E). H&E staining revealed that the combination treatment of ADR and PMI induced no pathological changes in the liver, kidney and heart compared to the control group (Fig. 4F). Immunohistochemistry showed that a high expression of Ki67 was exhibited in the control, while PMI combined with ADR decreased the expression of Ki67 in the tumor tissues (Fig. 4G). Taken together, we conclude that PMI enhanced ADR chemotherapy sensitivity in vivo.

**PMI combined with ADR inhibits phosphorylation of receptor tyrosine kinases in GC cell lines.** To further clarify how PMI acts as a regulatory factor in increasing the cell cytotoxicity of ADR, we examined the phosphorylation of receptor tyrosine kinases using a human RTK phosphorylation antibody array kit. SGC7901 cells were treated with ADR (1.0 µM) or the combination of PMI (50.0 µM) and ADR (1.0 µM) for 24 h. After normalization to the negative control (ADR), the phosphorylation of receptor tyrosine kinases was low in the drug combination group compared to the ADR group, including EGFR, FAK, Tyk2, ROS and LTK (Fig. 5A and B). Western blot assay showed that the expression levels of p-EGFR, EGFR, p-FAK and FAK were decreased in the drug combination group. However, the expression of cleaved PARP was upregulated and the expression of cyclin D1 was downregulated in SGC7901 cells treated with PMI combined with ADR (Fig. 5C and D).

**Discussion**

Reducing the side-effects of chemotherapy is a main strategy by which to improve the efficacy of chemotherapy. In China, traditional Chinese medicine (TCM) has been commonly used to improve cancer treatment efficiency in combination with chemotherapeutics serving as chemotherapeutic sensitizers. For example, increased attention has been paid to many TCM purification and monomers with low toxicity, high efficiency and safety in clinical practice.

Several TCM components have been used as chemotherapeutic sensitizers. For example, gambogenic acid was found to...
increase the chemosensitivity of breast cancer cells to adriamycin (ADR) by suppression of the PTEN/PI3K/AKT pathway leading to the apoptosis of MCF-7/ADR cells (10). Meanwhile, dioscin increased ADR chemosensitivity as it downregulated MDR1 expression by inhibiting the NF-κB signaling pathway in MCF-7/ADR cells (17). Quercetin was reported to enhance the sensitivity of breast cancer cells to doxorubicin by downregulating p-Akt expression arising from increased expression of PTEN (18). Cryptotanshinone enhanced the anticancer activity of doxorubicin in gastric cancer (GC) cells via STAT3 inactivation and suppression of STAT3-regulated antiapoptotic gene expression (19). Taken together, these agents serve as adriamycin sensitizers. The aim of the present study was to investigate whether PMI at non-toxic doses enhances the sensitivity of GC to ADR chemotherapy without additional toxicity. Our data demonstrated that the combination of PMI and ADR reduced cell viability as revealed by MTT assay. Compared with the PMI or ADR group, flow cytometry showed that the combination of PMI and ADR caused a marked induction in the apoptosis of GC cells. For the in vivo drug sensitivity experiment, mice received a dose of 2.5 mg/kg PMI which enhanced the chemotherapy sensitivity of ADR. Compared with the control group, the combination of ADR and PMI inhibited the tumor weight by 65.84%, while ADR could only
cause a decrease of 24.22%. However, H&E staining indicated no obvious abnormality after PMI plus ADR treatment, which demonstrated that PMI could be used as a chemotherapeutic sensitizer for the treatment of GC.

The epidermal growth factor receptor (EGFR) gene, a member of the EGFR family, encodes a 170 kDa transmembrane tyrosine kinase receptor (20). EGFR was found to be an independent predictor of poor prognosis as it was overexpressed in GC patients (21-23). Berberine effectively enhanced the activity of EGFR inhibitors (erlotinib and cetuximab) in vitro and in vivo in GC (24). The combination medication of β-elemene and gefitinib not only inhibited the survival and proliferation of glioblastoma multiforme cells via inhibition of the EGFR signaling pathway but also induced more distinct apoptosis and autophagy in the glioblastoma multiforme cells when compared with the gefitinib monotherapy (25). EGFR has been reported to be implicated in tumor progression and is also a crucial transmembrane signal transduction pathway for many solid tumors (26,27). To the best of our knowledge, EGFR is activated by ligand binding and succeeding receptor heterodimerization or homodimerization, which results in autophosphorylation of tyrosine residues and binding of adaptor molecules such as shc, gab-1 to the cytoplasmic domain. Src/FAK pathway is directly activated by phosphorylated receptors (28). Src/FAK and EGFR act synergistically through mutual phosphorylation and activation. The activation of EGFR enhanced Src expression contributed to tumor sensitivity of the Src inhibitor in lung cancer (29). In the present study, ADR combined with PMI downregulated the expression of p-EGFR and p-FAK, respectively.

FAK is widely known as a main mediator of migration, invasion, proliferation and oncogenic transformation (30). Recently, it has been reported to be involved in the pathogenesis of cancer. FAK is translocated to focal contact sites and autophosphorylated at its Tyr397 residue, which then leads to recruitment of downstream pathways by interacting with Src family kinases, PI3K, GRB7 and other signaling molecules (31). Increasing circumstantial evidence indicates that FAK overexpression contributes to the development of human malignancies, and has been acknowledged as an independent prognostic factor for...
The present study was supported by the Key Laboratory Program of Xinjiang Autonomous Region (no. 2014KLO06).

Acknowledgements

The present study was supported by the Key Laboratory Program of Xinjiang Autonomous Region (no. 2014KLO06).

References